Selected article for: "inflammatory disease and rheumatoid arthritis"
Author: López, Josué-Guillermo; Camacho-Barbosa, Jhyld-Carolaind; Felipe-Díaz, Oscar-Jair; Rojas-Zuleta, Wilmer-Gerardo; Ballesteros, Jesús-Giovanny; Navarro-Mendoza, Erika-Paola; Giraldo Herrera, Claudia-Lucía; Giraldo-Bustos, Rodrigo; Padilla-Tovar, Lácides; Duque-Zapata, Natalia; Orozco González, Catalina; López-Mora, María-José; Donado, Jorge-Hernando
Title: Recommendations for rheumatologists on pharmacological management during the COVID-19 health emergency: Expert group opinion
  • Cord-id: waqb1yta
  • Document date: 2021_4_12
    • ID: waqb1yta
    Snippet: Coronavirus 2019 (COVID-19) is an unexpected pandemic that has caused a state of emergency, as well as generating drastic changes in clinical care protocols. Some drugs commonly used in rheumatoid arthritis, systemic lupus erythematosus, and other systemic autoimmune diseases have been described for its treatment. Therefore, there is an imminent risk of shortages. The aim of this narrative review and expert opinion is to present general recommendations on the clinical and administrative manageme
    Document: Coronavirus 2019 (COVID-19) is an unexpected pandemic that has caused a state of emergency, as well as generating drastic changes in clinical care protocols. Some drugs commonly used in rheumatoid arthritis, systemic lupus erythematosus, and other systemic autoimmune diseases have been described for its treatment. Therefore, there is an imminent risk of shortages. The aim of this narrative review and expert opinion is to present general recommendations on the clinical and administrative management of outpatients with autoimmune or systemic inflammatory disease, in the context of the COVID-19 pandemic.

    Search related documents:
    Co phrase search for related documents
    • ace enzyme and acute respiratory virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
    • ace enzyme and additional treatment: 1
    • ace enzyme and local systemic: 1, 2, 3, 4
    • active disease and acute respiratory virus: 1, 2, 3
    • active disease and additional treatment: 1, 2
    • active disease and administrative clinical: 1
    • active disease and local systemic: 1, 2
    • active disease and low morbidity: 1
    • acute respiratory virus and additional treatment: 1, 2, 3, 4
    • acute respiratory virus and local systemic: 1, 2, 3
    • local systemic and low morbidity: 1